Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA)

Trial Profile

A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary) ; Ustekinumab
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 15 Jun 2024 Results of this study presented at the 25th Annual Congress of the European League Against Rheumatism
  • 15 Jun 2024 Results assessing characterize the efficacy of deucravacitinib by sex on clinical assessments and PROs in patients with PsA presented at the 25th Annual Congress of the European League Against Rheumatism
  • 15 Nov 2023 Results assessing the effect of deucravacitinib on pain across different instruments presented at the ACR Convergence 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top